Authors’ response: British Society of Gastroenterology guidelines on the diagnosis and management of coeliac disease

Gut ◽  
2015 ◽  
Vol 65 (4) ◽  
pp. 717.1-717 ◽  
Author(s):  
Andrew S Austin ◽  
Julia M Forsyth ◽  
Peter G Hill ◽  
Geoffrey K T Holmes
Gut ◽  
2014 ◽  
Vol 64 (4) ◽  
pp. 691-692 ◽  
Author(s):  
Peter Hill ◽  
Andrew Austin ◽  
Julia Forsyth ◽  
Geoffrey Holmes

Gut ◽  
2014 ◽  
Vol 63 (8) ◽  
pp. 1210-1228 ◽  
Author(s):  
Jonas F Ludvigsson ◽  
Julio C Bai ◽  
Federico Biagi ◽  
Timothy R Card ◽  
Carolina Ciacci ◽  
...  

2009 ◽  
Vol 68 (3) ◽  
pp. 249-251 ◽  
Author(s):  
Claire Stuckey ◽  
Jacqui Lowdon ◽  
Peter Howdle

It seems obvious to healthcare professionals that patients with coeliac disease should receive regular follow-up. Surprisingly, there is little evidence that patients benefit in terms of reduced morbidity or mortality. However, several authoritative bodies have published guidelines on the management of coeliac disease that recommend regular follow-up. There is good evidence that compliance with a gluten-free diet reduces the risk of complications such as osteoporosis or small bowel lymphoma. Compliance is enhanced particularly by education about the disease and the gluten-free diet and by support from peers or professionals. Such input can be provided by regular follow-up, which thereby should improve compliance and hence long-term health. The consensus of the recommendations for follow-up suggests an annual review by a physician and dietitian. At annual follow-up the disease status can be checked and nutritional advice can be given, including checking the adequacy of, and the compliance with, the gluten-free diet. Complications and associated medical conditions can be sought, genetic risks explained and support and reassurance given. Specialist dietitians have particular expertise in relation to diet and nutritional management; specialist clinicians have a broader range of expertise in many aspects of management of the disease. A team approach for providing follow-up is the ideal, with a clinician and dietitian, both with expertise in coeliac disease, being involved. No one particular group of healthcare professionals is necessarily better than the other at providing follow-up.


2020 ◽  
pp. flgastro-2020-101624
Author(s):  
Richard David Johnston ◽  
Ying Jenny Chan ◽  
Tayyib Mubashar ◽  
Joseph Robert Bailey ◽  
Siba Prosad Paul

Recent interim guidance from the British Society of Gastroenterology, aligned to historical paediatric practice, advises a no-biopsy protocol (NBP) for adults with high anti-tissue transglutaminase (tTG-IgA) titres and other clinical factors. A 7-year retrospective review identified 433 patients with positive tTG-IgA. Of these 433, 98 (23%) fulfilled the high titre criteria for an NBP which may have reduced endoscopic burden on the service. A high titre versus low titre translated in a 95% versus 75% histological confirmation of coeliac disease (p<0.01). The addition of anti-endomysial antibody analyses impacted minimally on these predictive rates. Our data support an NBP approach for selected patients. Of concern, however, was the finding that a third of patients with positive titres were not referred for a biopsy despite national guidance at the time advocating it. A clear message needs to be transmitted that the NBP is only for those with high titre, as opposed to any tTG-IgA positivity.


2020 ◽  
Vol 188 (6) ◽  
Author(s):  
Claire N. Harrison ◽  
Adam J. Mead ◽  
Mark W. Drummond ◽  
Gavin Chiu ◽  
Rozinder Bains

Sign in / Sign up

Export Citation Format

Share Document